Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


Safety and efficacy results of a phase iv safety-monitoring study of icotinib in treating advanced non-small cell lung cancer

  • In: SUBMITTED ORALS on Wednesday, 16 April 2014, 14:30-15:30
  • At: PSWC, Melbourne (Australia) (2014)
  • Type: Presentation
  • By: DING, Lieming (Betta Pharmaceuticals Co.,Ltd., Hangzhou, China)
  • Co-author(s): Tan, Fenlai (Betta Pharmaceuticals Co.,Ltd., Hangzhou, China)
    Han, Baohui (Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China)
    Hu, Xingsheng (Department of Medical Oncology, Cancer Institute/Hospital, CAMS & PUMC, Beijing, China)
    Zhang, Yiping (Zhejiang Cancer Hospital, Hangzhou, China)
    Liu, Xiguang (The Affiliated Hospital of Qingdao University, Qingdao, China)
    Sun, Yan (Department of Medical Oncology, Cancer Institute/Hospital, CAMS & PUMC, Beijing, China)
  • Abstract:

    Background: Icotinib was approved as a target therapy drug by China Food and Drug Administration for treating advanced non-small-cell lung cancer (NSCLC) based on its phase III ICOGEN trial. A safety-monitoring study was then conducted to assess the safety and efficacy of icotinib in a broader range of NSCLC patients. Methods: In this phase IV..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses